ANN ARBOR, Mich.--(BUSINESS WIRE)--RetroSense Therapeutics, a privately-held, clinical-stage biotechnology company, announced today that Therapeutic Area Partnerships has selected RetroSense lead compound, RST-001, as a “Top Project to Watch: Most Licensable Products” for the third consecutive year. RetroSense recently also won the “Deals of the Year” Research Award from MLive and Ann Arbor News.
RetroSense Therapeutics is at the forefront of developing optogenetic therapies for vision restoration.
RetroSense Therapeutics is at the forefront of developing optogenetic therapies for vision restoration.
